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A B S T R A C T
Purpose
To determine whether plasma estradiol (E2) levels are related to gene expression in estrogen
receptor (ER)–positive breast cancers in postmenopausal women.
Materials and Methods
Genome-wide RNA profiles were obtained from pretreatment core-cut tumor biopsies from 104
postmenopausal patients with primary ER-positive breast cancer treated with neoadjuvant anastrozole.
Pretreatment plasma E2 levels were determined by highly sensitive radioimmunoassay. Genes were
identified for which expression was correlated with pretreatment plasma E2 levels. Validation was
performed in an independent set of 73 ER-positive breast cancers.
Results
The expression of many known estrogen-responsive genes and gene sets was highly significantly
associated with plasma E2 levels (eg, TFF1/pS2, GREB1, PDZK1 and PGR; P  .005). Plasma E2
explained 27% of the average expression of these four average estrogen-responsive genes (ie,
AvERG; r  0.51; P  .0001), and a standardized mean of plasma E2 levels and ER transcript levels
explained 37% (r, 0.61). These observations were validated in an independent set of 73 ER-positive
tumors. Exploratory analysis suggested that addition of the nuclear coregulators in a multivariable
analysis with ER and E2 levels might additionally improve the relationship with the AvERG. Plasma E2
and the standardized mean of E2 and ER were both significantly correlated with 2-week Ki67, a
surrogate marker of clinical outcome (r  0.179; P  .05; and r  0.389; P  .0005, respectively).
Conclusion
Plasma E2 levels are significantly associated with gene expression of ER-positive breast cancers
and should be considered in future genomic studies of ER-positive breast cancer. The AvERG is
a new experimental tool for the study of putative estrogenic stimuli of breast cancer.
J Clin Oncol 28:1161-1167. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Approximately 80% of invasive breast cancers
present in developed countries as estrogen receptor
(ER)–positive and are usually treated with endo-
crine therapy in the form of antiestrogens or estro-
gen suppressants—aromatase inhibitors (AIs) in
postmenopausal women. ER-positive tumors, al-
though highly heterogeneous, consists largely of tu-
mors described as luminal1 and are now recognized
as being genetically distinct from ER-negative tu-
mors. There is considerable clinical interest in iden-
tifying molecular factors that reflect the variable
dependence of ER-positive tumors on estrogenic
stimulation and, by extension, the likelihood of
these tumors benefiting from endocrine therapy2;
however, few genomic studies have focused specifi-
cally on the ER-positive subgroup.
Although expression of progesterone recep-
tor (PgR), which is strongly influenced by estro-
gens in vitro3 and in vivo,4-6 has been evaluated in
this manner, it is clear that, as a single factor, PgR
does not fully reflect estrogen dependence: many
PgR-negative tumors respond to tamoxifen or AIs.7,8
Trefoil factor 1 (TFF1), originally known as pS2, is
used often as a marker in laboratory studies9 but
infrequently for clinical studies. Other studies of
ER-positive breast cancer cells in vitro have identi-
fied additional genes for which expression is depen-
dent on estrogenic stimulation,10 but most have not
been translated to clinical utility.
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Plasma levels of estradiol (E2) vary markedly between post-
menopausal women and are significantly correlated with risk of
development of breast cancer.11 Exogenous estrogens increase risk,
particularly when administered with progestins.12 Plasma levels of
endogenous E2 are, however, not known to influence breast cancer
biology significantly; conversely, it is widely considered that intra-
tumoral synthesis of estrogens provides the predominant estro-
genic influence.13
The primary objective of this study was to determine whether
plasma E2 levels correlated with gene expression in ER-positive
breast cancers and, if so, whether associated genes were known to
be estrogen regulated. Secondary objectives were to determine the
relative contribution of plasma E2 and ESR1 expression levels to any
associations with estrogen-regulated genes and to assess the relation-
ship of these genes with clinical and biologic measures of clinical
efficacy of estrogen deprivation (ie, aromatase inhibition). Explor-
atory analyses included an assessment of the relationship of steroid
receptor coregulators with expression of estrogen-regulated genes.
MATERIALS AND METHODS
Patient Samples
Core-cut tumor biopsies (14-gauge) were obtained from 112 postmeno-
pausal women with stage I to IIIB, ER-positive, early breast cancer before and
after 2 weeks of anastrozole treatment in a neoadjuvant trial.14 Patients who
received gefitinib during the first 2 weeks were excluded. Tissue was later
stored in RNA (Ambion, Austin, TX) at 20°C. Two 4-m sections from the
core were stained with hematoxylin and eosin to confirm the presence of
cancerous tissue and the histopathology. Total RNA was extracted by using
RNeasy (Qiagen, Sussex, United Kingdom). RNA quality was checked by
using an Agilent Bioanalyser (Agilent Technologies, Santa Clara, CA): samples
with RNA integrity values less than 5 were excluded from additional analysis.
ER status and Ki67values by immunohistochemistry were already available.14
The validation set was derived from baseline frozen biopsy samples obtained
from 73 patients receiving neoadjuvant letrozole therapy in a phase II clini-
cal trial.15
Gene Expression Analysis and Data Preprocessing
RNA amplification, labeling, and hybridization on HumanWG-6 v2
Expression BeadChips (Illumina, San Diego, CA) were performed according
to the manufacturer’s instructions at a single Illumina BeadStation facility.
Tumor RNA of sufficient quality and quantity was available to generate ex-
pression data from 104 pretreatment biopsies. Data was extracted by using
BeadStudio (Illumina) software and was normalized with variance-stabilizing
transformation (VST) and Robust Spline Normalization method in the Lumi
package.16 Probes that were not detected in any samples (detection P  1%)
were discarded from additional analysis. The gene expression approach (Agi-
lent Technologies) and gene expression data sets for the validation study are
described in Crowder et al.17
Data Analysis
Primary analysis. Multiple correlation analysis was performed in BRB-
Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). A statistical sig-
nificance level for each gene for testing the hypothesis that the Spearman
correlation between gene expression and plasma estradiol was zero was calcu-
lated, and P values then were used in a multivariate permutation test,18 from
which false discovery rates were computed. Gene set enrichment analysis
(GSEA) was carried out on the ranked lists of correlated genes by using the
GSEA preranked function of the software across the curated gene sets of the
Broad Institute Molecular Signatures Database (MSigDB).19 Pathway analysis
by using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA)
was conducted on the list of genes correlated with P  .005. Other statistical
analyses were performed in SPSS for Windows (SPSS, Chicago, IL), S-Plus
(TIBCO Software, Palo Alto, CA), and Graphpad Prism (Graphpad Software,
La Jolla, CA).
Intrinsic subtypes were assigned with a 50-gene subtype predictor.20
Data from the exclusively ER-positive tumors in this study were normalized
before subtyping analysis with data from an additional 64 tumors, including 23
ER-negative cancers, analyzed concurrently on Illumina arrays.
Secondary and exploratory analyses. Multivariable analysis was per-
formed in a forward stepwise fashion, and the most significant additional
variable (satisfying P  .05) was added at each stage. Occurrences with missing
values for any of the variables in the model were excluded from analysis
(Appendix Table A1). Statistically significant results were assessed when data
availability allowed in the validation set.
Table 1. Genes Positively Correlated With Plasma Estradiol Concentration
Spearman
Rank Gene Symbol Genbank Accession No.
Spearman Correlation
Coefficient Parametric P Known Estrogenic Function
1 TFF1 NM_003225 0.469 7.00E-07 Estradiol-responsive gene in vitro and in vivo10,22,23
2 CAPN2 NM_001748 0.430 6.40E-06
3 CAPN9 NM_016452 0.378 .73E-05
4 UNG2 NM_021147 0.374 .0001027
5 GREB1 NM_148903 0.360 .0001955 Estradiol-responsive gene in vitro and in vivo10,22-24
6 RAGE NM_014226 0.357 .0002178 Estradiol-responsive gene in vitro25
7 BTD NM_000060 0.346 .000348
8 VN1R2 NM_173856 0.344 .000378
9 TLE1 NM_005077 0.337 .0005016
10 SPG3A NM_181598 0.336 .0005227
14 AZGP1 NM_001185 0.329 .0006986 Estradiol-responsive gene in vivo22
31 PDZK1 XM_943050 0.310 .0014502 Estradiol-responsive gene in vitro and in vivo10,22,23
57 SERPINA3 NM_001085 0.298 .0022427 Estradiol-responsive gene in vivo23
59 IRS1 NM_005544 0.297 .0022581 Estradiol-responsive gene in vitro26
75 TFF2 NM_005423 0.290 .0029109 Estradiol-responsive gene in GI tract27
85 PGR NM_000926 0.286 .0034066 Established measure of estrogenicity3
119 TFF3 NM_003226 0.276 .0047773 Estradiol-responsive gene in vivo23
NOTE. Ranked according to Spearman correlation. The 10 most strongly correlated genes are shown together with genes known to be associated with estrogen
signaling with P  .005.
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Blood Samples and Hormone Measurement
Baseline plasma E2 levels before anastrozole or letrozole treatment were
determined by a highly sensitive radioimmunoassay after ether extraction21 by
using rabbit antiserum against an estradiol-6-carboxymethyloxime-BSA con-
jugate (EIR, Wurenlingen, Switzerland) and estradiol iodine 125 reagent DSL
4420 from the estradiol RIA kit DSL 4800 (Beckman Coulter [formerly known
as DSL], Fullerton, CA). Sensitivity was 3 pmol/L by calculation from the 95%
CIs of the zero standard. Plasma samples from both the anastrozole and
letrozole cohorts were analyzed in the same laboratory.
RESULTS
Relationship of Plasma E2 With Tumor
Gene Expression
Quantitative trait analysis (QTA) by Spearman correlation was
used to identify 226 genes from the 25,386 filtered genes for which
expression in tumor biopsies correlated with plasma E2 levels at a
P  .005 (Table 1). Genes previously known to be associated with a
transcriptional response to estrogen appeared to be overrepresented
among the genes closely correlated with plasma E2. TFF1 expression
correlated most highly with pretreatment plasma E2 levels (Fig 1A).
GREB1 (gene regulated by estrogen in breast cancer), an early re-
sponse gene in the estrogen receptor-regulated pathway,22,24 (Fig 1B)
was the fifth-most positively correlated gene, whereas expression of
the PGR, the gene encoding the progesterone receptor, was also signif-
icantly correlated (P  .003). Plasma E2 levels were significantly
higher in patients with immunohistochemical (IHC) PgR-positive
tumors than in those with PgR-negative tumors (medians, 35 and 23
pmol/L, respectively; P .0002). There was no significant relationship
between plasma E2 and ER IHC levels. Plasma E2 did not correlate
with either nodal status or tumor size (P  .55 and 0.52, respectively).
GSEA19 revealed that gene sets associated with the transcriptional
response to estrogen deprivation in other published data sets were
significantly enriched in the genes most tightly correlated with pre-
treatment plasma E2 levels. In particular, the genes identified as regu-
lated in vitro by E2 through ER- and ER-28 were statistically
significantly enriched (q value,  0.2; Table 2). Pathway analysis by
using Ingenuity software on the 98 annotated genes positively corre-
lated with plasma E2 levels (P  .005) and revealed a network showing
a significant relationship between 29 of these genes (Fig 2).
For additional analysis, an index of estradiol-responsive genes
was generated by averaging the expression of four key genes, which
was denoted AvERG (ie, average estrogen-responsive genes). TFF1,
GREB1, and PDZK1 were selected for this index as the highest ranked
genes in our analysis that had been responsive to estrogen deprivation
with AIs in the two published clinical studies available to date22,23 and
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Fig 1. Correlation of plasma estradiol and
estrogen-responsive gene expression. (A)
Plasma estradiol versus TFF1 expression in
discovery data set. (B) Plasma estradiol ver-
sus GREB1 expression in discovery data
set. (C) Plasma estradiol versus AvERG (av-
erage estrogen-responsive genes; ie, mean
of TFF1, GREB1, PDZK1, and PGR) expres-
sion in discovery data set. (D) Plasma
estradiol versus AvERG expression in in-
dependent validation data set.
Table 2. Gene Set Enrichment Analysis of Genes Positively Correlated









Stossi_ER_up 25 1.723829 0 0.086808
Breast_cancer_estrogen_signaling 54 1.678478 0 0.102272
Falt_bcll_Ig_mutated_v_wt_up 20 1.652155 .002028 0.112083
Creb_brain_8weeks_dn 24 1.588765 .002006 0.238964
Lee_cip_dn 23 1.57291 .003009 0.246045
Uvb_nhek1_c1 20 1.555116 .00402 0.268565
Ros_mouse_aorta_dn 43 1.545233 0 0.268399
BRCA_er_pos 291 1.533465 0 0.278001
Nab_lung_dn 26 1.532062 .007 0.251437
Basso_germinal_center_cd40_dn 28 1.511978 .003006 0.296837
Frasor_ER_dn 27 1.509353 .006006 0.279102
Aged_mouse_cerebellum_up 31 1.496655 .006018 0.280914
Basso_germinal_center_cd40_dn 28 1.511978 .003006 0.296837
Abbreviation: FDR, false discovery rate.
Estradiol-related pathway.
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in the key published in vitro study of estradiol-stimulated genes in
breast cancer cells.10 PGR was included, as it has been identified as a
marker of estrogenicity in numerous studies spanning 3 decades3 and
is in routine clinical use. No other combination of genes was tested.
The resultant index correlated with plasma E2 levels with r  0.51
(P  .0001; Fig 1C).
Validation of Association Between Plasma E2 and
AvERG Expression
To determine the validity of these observations, we tested the four
key estradiol-dependent genes in an independent group of ER-
positive breast cancer samples from postmenopausal patients before
treatment in a phase II trial of neoadjuvant letrozole.15 Plasma taken at
diagnosis and Agilent microarray measurements from tumors were
available from 73 patients. Of the four classical estrogen-dependent
genes identified in our discovery set (ie, TFF1, GREB1, PDZK1, and
PGR) only PGR was not individually significantly correlated with
plasma E2 (P  .05), whereas the AvERG correlated overall with
r  0.32 (P  .006; Fig 1D). The CIs for the correlation coefficients for
PGR in the two sample sets overlapped markedly, which indicated no
significant heterogeneity despite the lack of statistical significance in
the validation set (initial samples: r  0.25; 95% CI, 0.053 to 0.44;
validation samples: r  0.17; 95% CI  0.072 to 0.39). Similarly,
plasma E2 levels were higher in PgR-positive (by IHC) than PgR-
negative occurrences in the validation set, but this was not statistically
significant (P  .17).
Contribution of ESR1 Levels to AvERG
Gene Expression
As E2 induces transcription primarily through ER- (ESR1) in
breast carcinomas, we investigated the effect of ESR1 levels, as mea-
sured by cDNA microarray analysis, on AvERG. ESR1 expression was
Fig 2. Map showing relationship between genes positively correlated with plasma estradiol superimposed on Ingenuity map. Pathway analysis was carried out on 98
positively correlated genes (P  .005), and functional annotation revealed a network of 29 genes related through known estradiol- and progesterone-related signaling
pathways. Genes correlated with plasma estradiol are shown in red, and the intensity of red coloration reflects the degree of correlation.
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correlated with AvERG in our original data set (r  0.27; P  .006)
and not with plasma E2 levels (r  0.01; P  not significant). On
multivariable analysis, variation in plasma E2 and ESR1 were
found to account for 27% and 10% of the variation in AvERG,
respectively. The correlation of the AvERG with a normalized
mean of plasma E2 and ESR1 was 0.61 (P  .0001; Fig 3A).
Equivalent analysis of the validation samples found plasma E2 and
ESR1 levels accounted for 18% and 15% of the variation in AvERG,
respectively, with analysis that included ESR1 levels producing a
correlation of r  0.54 (P  .0001; Fig 3B).
Contribution of Cofactor Levels to AvERG
Gene Expression
Coactivators and corepressors interact with the bound ER to
modulate gene transcription.29 To assess the role that levels of the
primary coactivators and corepressors have on estrogen-dependent
gene expression, univariate analysis was undertaken with AvERG ex-
pression as the dependent variable and the following coregulators:
NCOR1, NCOR2, NCOA1, NCOA2, and NCOA3 as potentially inde-
pendent covariables. Significant associations were found with NCOR1
(P  .002), NCOA1 (P  .03), and NCOA3 (P  .01). Inclusion of
these three factors with plasma E2 and ESR1 in a multivariable analysis
revealed log plasma E2 (P  .001), ESR1 (P  .001), and NCOR1
(P  .007) to be independently significant with these factors, which
explained 41% of the variation in AvERG expression. None of the
cofactors were found to be significant on equivalent analysis of the
independent data set, but the Agilent platform provided a lower dy-
namic range of expression values.
Relationship of Pretreatment Plasma E2 and AvERG
With Intrinsic Subtype Status
Intrinsic subtype was ascribable to 69 tumors: 35 luminal A, 17
luminal B, 12 HER2-like, and five basal-like tumors. AvERG and
plasma E2 were significantly higher in luminal A tumors compared
with the other sets, when considered together (P  .008 and 0.011,
respectively). Differences of similar magnitude were present between
luminal A and B tumors when considered separately, but the signifi-
cance levels were lower because of fewer numbers (P  .097 and
0.040, respectively).
Relationship of Pretreatment Plasma E2 With Ki67
Staining After 2 Weeks of Treatment
With Anastrozole
We have previously reported that higher Ki67 expression after 2
weeks of endocrine therapy is significantly associated with lower
recurrence-free survival.30 To determine whether pretreatment
plasma estradiol and/or ESR1 levels affect this potential surrogate
marker for outcome, we investigated the relationship between plasma
E2 and the standardized mean of plasma E2 and ESR1 with the level of
tumor Ki67 expression after 2 weeks of treatment. Plasma E2 and the
standardized mean were both significantly correlated with 2-week
Ki67, although this was borderline for the former (r  0.179;
P  .05; and r  0.389, P  .0005, respectively; Fig 4).
Relationship of Pretreatment Plasma E2 and AvERG
With Clinical Response
We conducted an exploratory analysis to determine whether
pretreatment plasma E2 and/or AvERG correlated with clinical re-
sponse in the approximately 50% of the patients that received anas-
trozole alone for their complete courses of neoadjuvant therapy. In
each occurrence, there was a trend toward higher levels in the
complete and partial responders versus in those who showed stable
A
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Fig 3. (A) Standardized mean of plasma
estradiol and ESR1 expression versus AvERG
(average estrogen-responsive genes; ie,
mean of TFF1, GREB1, PDZK1, and PGR)
expression in discovery data set. (B) Stan-
dardized mean of plasma estradiol and
ESR1 expression versus AvERG expression
in independent validation data set.
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Fig 4. Standardized mean of plasma estradiol and ESR1 expression versus Ki67
percentage staining 2 weeks after anastrozole treatment.
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disease or progression. However, in neither instance was this close
to statistical significance (P  .16 for n  50; and P  0.17 for
n  51, respectively).
DISCUSSION
This study is the first to show a relationship between the expression of
estrogen-dependent genes in ER-positive breast carcinomas and basal
levels of estrogen. Although such results may not appear surprising,
findings that intratumoral E2 levels are 10 to 20 times higher than
those in plasma, and the absence of a reported correlation between
levels in the two compartments, have led to the view that intratumoral
estrogen synthesis has a greater influence on estrogen signaling than
uptake from the circulation.13 The data presented in this article chal-
lenge that view and strongly suggest that differences in plasma E2
levels between patients have a significant influence on breast tumors.
In particular, this influence may be important to consider in future
genomic studies of ER-positive breast cancer, and this may extend to
premenopausal women in whom the within-patient changes in E2
levels through the menstrual cycle are marked. Our data relating to
Ki67 also suggest that E2 levels merit additional investigation in rela-
tion to their possible influence on disease outcome on AIs.
The strength of the relationship between AvERG and plasma E2
levels in this heterogeneous group of ER-positive tumors is remark-
able. The relationship was replicated in an independent sample set
with good statistical confidence, despite a smaller sample size. The low
plasma levels of E2 in postmenopausal women measured in this study
would be unquantifiable by most routinely used assays31 and may be
one reason that this relationship has not been previously observed.
Additional exploration should be conducted only with the use of such
specialist assays. In a model system, proportional uptake of E2 from
plasma was inversely related to plasma E2 concentrations.32 Our data
do not allow us to determine whether this inverse relationship extends
to the expression of estrogen-related genes.
The inclusion of ESR1 mRNA expression as a variable along with
plasma E2 explained 37% of the variability in the AvERG. There is
sufficient unexplained variability for intratumoral synthesis to make a
meaningful contribution, but analytic imprecision and other factors
also may be influential. One such potential influence examined in this
study is the expression of nuclear coregulators.29 Additional explor-
atory modeling that allowed for an interaction between the five co-
regulators and ER explained 54% of the variability in AvERG (data not
shown). These relationships were not confirmed in the validation set,
possibly because of the lower dynamic range on the Agilent platform.
These apparent relationships need additional study before they could
be considered reliable.
The absence of a relationship between plasma E2 and ESR1
expression and the known effect of estrogen deprivation on the index
genes suggest that the relationship between plasma E2 and these estro-
gen index genes is due to signaling influences rather than to the
evolution of particularly estrogen-sensitive tumors as a result of higher
E2 levels. As well as providing evidence for the importance of basal
levels of E2 on breast cancer biology, the creation of AvERG provides
a new index for understanding the clinical and biologic importance of
other putative estrogenic influences. For example, a number of ste-
roids thought of largely as androgens also have been found to have
significant estrogenic activity in vitro,33,34 and it has been speculated
that these may be particularly important in patients under treatment
with AIs. They would not be expected to be influenced by such treat-
ment; as a result, they may provide a possible resistance mechanism.33
Assessment of the AvERG in relation to plasma levels of these andro-
gens in AI-treated patients would provide evidence for or against the
clinical importance of their estrogenic activity. The AvERG also may
be useful as an end point in characterizing the pathologic impact of
polymorphic genetic differences in components of the estrogen re-
sponse mechanism (eg, ESR1, coregulators) in breast tumors.
Our selection of the four index genes to create the AvERG was
based on the well-established estrogen sensitivity of these genes as
recorded in numerous publications and, therefore, minimized the
potential for false discovery in their selection from tens of thousands of
genes. It is likely that, as a result, the current AvERG will not be the
most sensitive possible marker of estrogenic activity and that an opti-
mally selected gene set could lead to an improved AvERG.
There are few data assessing the relationship of plasma estrogen
levels and outcome of therapy,35 but the weak, significant relationship
of baseline plasma E2 level with the value of Ki67 after 2 weeks of
aromatase inhibition, a marker we have previously found related to
recurrence-free survival,30 suggests that this merits evaluation in large
cohorts of patients. The lack of a significant correlation between either
plasma E2 or AvERG with clinical response was not surprising given
the small patient cohort available. In addition, we have previously
found that Ki67 at 2 weeks is a better predictor of long-term outcome
on endocrine therapy than clinical response.30 The higher levels of
plasma E2 and AvERG in luminal A tumors compared with the other
subtypes is consistent with the expression in this group of many
ER-related genes.1
Plasma estrogen and androgen levels are significantly correlated
with one another. For example, in published data from our laborat-
ory,36 log plasma E2 and log plasma testosterone showed r2  0.31 in
greater than 2,000 samples from postmenopausal women (correlation
data unpublished). This raises the possibility that the correlation be-
tween plasma E2 and AvERG could be due in part to plasma testoster-
one action as a substrate for intratumoral aromatization. Plasma
samples from this study, unfortunately, were lost in a fire, which
prevented measurements of testosterone to assess this possibility.
In conclusion, this assessment of plasma E2 levels in association
with genome-wide expression studies has revealed new relationships
that are likely to be important for additional genomic studies of ER-
positive breast cancer, for the assessment of multiple putative estro-
genic influences on breast cancer, and possibly for clinical outcome
after estrogen deprivation therapy.
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